5-{5-phenyl-6-[4-({4-[5-(pyridin-2-yl)-1H-pyrazol-3-yl]piperidin-1-yl}methyl)phenyl]pyridin-3-yl}-1,3,4-thiadiazol-2-amine | 791851-26-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 5-{5-phenyl-6-[4-({4-[5-(pyridin-2-yl)-1H-pyrazol-3-yl]piperidin-1-yl}methyl)phenyl]pyridin-3-yl}-1,3,4-thiadiazol-2-amine
• 英文别名: 5-[5-phenyl-6-[4-[[4-(3-pyridin-2-yl-1H-pyrazol-5-yl)piperidin-1-yl]methyl]phenyl]pyridin-3-yl]-1,3,4-thiadiazol-2-amine
• CAS: 791851-26-8
• 化学式: C₃₃H₃₀N₈S
• 分子量: 570.721
• InChiKey: IOTHDTICZAKUMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  5-phenyl-6-(4-((4-(5-(pyridin-2-yl)-1H-pyrazol-3-yl)piperidin-1-yl)methyl)phenyl)nicotinonitrile 、 氨基硫脲 在 三氟乙酸 作用下， 反应 16.0h， 以79%的产率得到5-{5-phenyl-6-[4-({4-[5-(pyridin-2-yl)-1H-pyrazol-3-yl]piperidin-1-yl}methyl)phenyl]pyridin-3-yl}-1,3,4-thiadiazol-2-amine
  参考文献：
  名称：

  Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors

  摘要：

  This letter shows inhibitor SAR on a pyridine series of allosteric Akt inhibitors to optimize enzymatic and cellular potency. We have optimized 2,3,5-trisubstituted pyridines to give potent Akt1 and Akt2 inhibitors in both enzyme and cell based assays. In addition, we will also highlight the pharmacokinetic pro. le of an optimized inhibitor that has low clearance and long half-life in dogs. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.040

文献信息

• Inhibitors of akt activity
  申请人：Bilodeau T Mark

  公开号：US20070043001A1

  公开（公告）日：2007-02-22

  The present invention is directed to compounds which contain a substituted pyridine moeity which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

  本发明涉及化合物，其中包含取代的吡啶基团，可抑制Akt蛋白激酶的活性。本发明还涉及含有本发明化合物的化疗组合物和治疗癌症的方法，包括给予本发明化合物的治疗方法。
• INHIBITORS OF AKT ACTIVITY
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1622616B1

  公开（公告）日：2011-06-15
• US7579355B2
  申请人：——

  公开号：US7579355B2

  公开（公告）日：2009-08-25
• [EN] INHIBITORS OF AKT ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITE AKT
  申请人：MERCK & CO INC

  公开号：WO2004096131A2

  公开（公告）日：2004-11-11

  The present invention is directed to compounds which contain a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
• Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors
  作者：John C. Hartnett、Stanley F. Barnett、Mark T. Bilodeau、Deborah Defeo-Jones、George D. Hartman、Hans E. Huber、Raymond E. Jones、Astrid M. Kral、Ronald G. Robinson、Zhicai Wu

  DOI：10.1016/j.bmcl.2007.12.040

  日期：2008.3

  This letter shows inhibitor SAR on a pyridine series of allosteric Akt inhibitors to optimize enzymatic and cellular potency. We have optimized 2,3,5-trisubstituted pyridines to give potent Akt1 and Akt2 inhibitors in both enzyme and cell based assays. In addition, we will also highlight the pharmacokinetic pro. le of an optimized inhibitor that has low clearance and long half-life in dogs. (C) 2007 Elsevier Ltd. All rights reserved.